Clinical trials: Influenza Virus
Influenza
A Study to Assess the PK of AL-794 Formulations in Healthy Subjects
This study is a single-center, randomized, open-label crossover study to assess the pharmacokinetics and food effect of AL-794 formulations in healthy subjects.
- Trial name
- NCT02877160
- Testing
- AL-794 suspension, AL-794 tablet
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Influenza
Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza
The purpose of this study is: to assess clinical efficiency of Ergoferon for treatment of influenza to assess safety of Ergoferon for treatment of influenza to compare efficiency of Ergoferon and Tamiflu for treatment of influenza
- Trial name
- NCT01804946
- Testing
- Ergoferon, Oseltamivir
- Where
- 8 sites in Russia
- Volunteers
- 161 people
- Sponsor
- Materia Medica Holding
Influenza
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
The purpose of this study is to evaluate the safety , tolerability and pharmacokinetics after multiple ascending of HNC042 given to healthy Chinese volunteers, compared to placebo.
- Trial name
- NCT04603989
- Testing
- HNC042 for Injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Influenza
Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses
The purpose of this study is to assess in healthy subjects the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses of CR8020, a monoclonal antibody against influenza A viruses.
- Trial name
- NCT01756950
- Testing
- 2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older
The purpose of this study is to comply with the post marketing condition to the exceptional approval of Arepanrix™ in Japan and to assess the immunogenicity and safety of GSK Biologicals' H1N1 influenza vaccine healthy Japanese…
- Trial name
- NCT01114620
- Testing
- Arepanrix™
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
The primary objectives of this study were: To describe the immunogenicity of the 2018-2019 formulation of Fluzone® Quadrivalent vaccine in children 6 to less than (<) 36 months of age and 3 to <9 years of age, and in adults 18 to…
- Trial name
- GRC90 (NCT03617523)
- Testing
- Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
- Where
- 3 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Pandemic Influenza
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
The objectives of this study are to assess the dose-related safety and immunogenicity of six different dose levels of inactivated, Vero cell-derived reverse genetic reassortant A/H5N1/Indonesia/05/2005 influenza vaccine in a…
- Trial name
- NCT00783926
- Testing
- H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
- Where
- 6 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged >=18 years.
- Trial name
- NCT00719043
- Testing
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 13 sites in United States, Canada
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old
This is an open study of the use of AdimFlu-V (2012-2013 season) vaccine in young healthy subjects. Subjects aged equal to or over 9 years old and less than 18 years old will receive one dose of vaccine (0.5 mL) by intramuscular…
- Trial name
- NCT01755364
- Testing
- AdimFlu-V
- Where
- Taiwan
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza
Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control of a pandemic will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00309647
- Testing
- Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine, Influenza Monovalent Whole virus (H5N1)
- Where
- 9 sites in Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™
This study is designed to assess the immunogenicity, reactogenicity and safety following vaccination with GSK Biologicals' Fluarix vaccine in children who have previously been vaccinated with two doses of Pandemrix at the age of…
- Trial name
- NCT01196026
- Testing
- Fluarix™, Havrix™ Junior
- Where
- 7 sites in Netherlands, Sweden
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety Study of Single Administration Intravenous Treatment for Influenza
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-7100, a candidate treatment for influenza.
- Trial name
- NCT01375985
- Testing
- AVI-7100
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Influenza A H3N2
Study Examining PrEP-001 in Healthy Subjects
Phase 2 study, looking at the prophylactic efficacy, safety and tolerability to a repeated nasal dose of study drug after being infected with Influenza A/Perth/16/2009 (H3N2) virus.
- Trial name
- NCT03220048
- Testing
- PrEP-001
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hvivo
Preventive Medicine
Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI
The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children…
- Trial name
- NCT03301155
- Testing
- Anaferon for children
- Where
- 33 sites in Russia, Uzbekistan
- Volunteers
- 1,036 people, healthy volunteers welcome
- Sponsor
- Materia Medica Holding
Influenza, Influenza, Human
Revaccination With Influenza Vaccine GSK1247446A
The protocol is designed to demonstrate the safety of influenza vaccine GSK1247446A after revaccination.
- Trial name
- NCT00545025
- Testing
- Influenza Vaccine GSK1247446A, Fluarix™
- Where
- Belgium
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
The purpose of this study is to comply with the European Medicines Agency (EMA) guidance on enhanced safety surveillance for seasonal influenza vaccines in the European Union (EU) and aims to assess adverse events of interest…
- Trial name
- NCT03688620
- Testing
- Passive enhanced safety surveillance
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 1,060 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' influenza vaccine in children aged 3 to 17 years.
- Trial name
- NCT01379937
- Testing
- Influenza vaccine GSK1562902A Formulation 1, Influenza vaccine GSK1562902A Formulation 2, Havrix™
- Where
- 2 sites in Philippines
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control
Children younger than 5 years of age are at high risk for severe influenza disease (flu) and hospitalization due to flu. Scientists are in the process of re-evaluating the dosing initially based on whole virus vaccines to improve…
- Trial name
- NCT00778895
- Testing
- GSK Biologicals' influenza vaccine GSK1557482A, Vaxigrip
- Where
- 18 sites in Canada
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
This is an observer-blinded, randomized, placebo-controlled, parallel group study to evaluate safety and immunogenicity of TAP-V001 quadrivalent influenza vaccine in healthy adult subjects.
- Trial name
- NCT04439695
- Testing
- Low dose, Intermediate dose, High dose
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- KBio Inc
Influenza
Study to Evaluate an Influenza Vaccine Candidate
The purpose of this study is to evaluate the immune response and safety of influenza vaccine candidate with or without adjuvant compared to Fluarix™ administered intramuscularly in elderly aged 60 years old and above.
- Trial name
- NCT00321373
- Testing
- Candidate Influenza Vaccine GSK1247446A - 2 different formulations, FluarixTM
- Where
- 17 sites in Finland, Greece
- Volunteers
- 1,220 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.